This investigational research study evaluated the dose response of once-weekly injections in patients with Type 2 Diabetes between 18 and 64 years of age.
The total study participation was approximately 1 year.
- Generally adults; 18-64 years of age
- BMI ≥0 kg/m2
- Diagnosed with Type 2 Diabetes
- Had an HbA1c between 7.0-10.5%